This module will review and discuss the pathophysiology and epidemiology of multiple myeloma (MM), factors influencing treatment selection, symptom management, and supportive care. This module will also provide an in depth review of the hallmark clinical trials, efficacy and safety, monitoring, adherence and compliance, and sequencing of therapies. Oncology pharmacists play an integral role in the management of patients with MM and should be knowledgeable of management strategies to ensure optimal outcomes.
- Recognize the pathophysiology, etiology, clinical symptoms, cytogenetic aberrations, and epidemiology of multiple myeloma
- Choose an individualized therapeutic plan based on the assessment of patient information, available evidence and treatment guidelines for the management of multiple myeloma
- Modify treatment and monitoring plans for patients with multiple myeloma in order to optimize safety, clinical outcomes, and adherence
Speaker: Kirollos Hanna, PharmD, BCOP, BCPS
Disclosure: Kirollos Hanna- Seattle Genetics- Advisory Board Member, Speaker Bureau, Consultant - Honoraria, Hyloris Pharmaceuticals- Consultant - Honoraria, Abbvie – Speaker Bureau - Honoraria, Taiho Oncology- Advisory Board Member - Honoraria, Rigel Pharmaceuticals- Advisory Board Member - Honoraria, Sandoz – Advisory Board Member - Honoraria, Incyte Corporation- Advisory Board Member - Honoraria, AstraZeneca- Advisory Board Member - Honoraria, Exelixis- Advisory Board Member - Honoraria, Astellas- Advisory Board Member - Honoraria, CVS- Stockholder, Employee
Target Audience: This activity is intended for beginner/intermediate/advanced hematology/oncology pharmacists.
Activity Type: Application